Entrada Therapeutics Q3 net loss widens to $44.1 mln

Entrada Therapeutics

06/11/2025 12:14

Overview

Entrada Therapeutics Q3 net loss widens to $44.1 mln from $14.0 mln last year

Collaboration revenue drops to $1.6 mln from $19.6 mln due to plan completion

Company extends cash runway into Q3 2027 with $327 mln in cash and securities

Outlook

Entrada expects to report ELEVATE-44-201 data in Q2 2026

Company plans to report ELEVATE-45-201 data in mid-2026

Company's cash runway extended into Q3 2027

Result Drivers

DMD PROGRAM COSTS - Increased R&D expenses driven by costs related to DMD programs and higher personnel expenses

COLLABORATION REVENUE DECLINE - Revenue drop attributed to completion of collaboration with Vertex

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Collaboration Revenue
$1.61 mln
Q3 EPS
-$1.06
Q3 Net Income
-$44.13 mln
Q3 Income From Operations
-$47.05 mln
Q3 Operating Expenses
$48.67 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Entrada Therapeutics Inc is $18.50, about 62.5% above its November 5 closing price of $6.94

Press Release: ID:nGNX3s0t0P

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)